Vantas Valera Pharmaceuticals - Treatment for Prostate Cancer
Vantas is a long-acting implant designed for the continuous
12-month administration of histrelin, a synthetic nonapeptide
agonist of luteinizing hormone-releasing hormone (LHRH). Vantas is
indicated for the palliative treatment of advanced prostate cancer.
Posted: October 2004
Vantas (histrelin) FDA Approval History